Table 1. Clinical characteristics of 857 allo-HSCT patients transplanted at Memorial Sloan Kettering Cancer Center.

NHL, non-Hodgkin’s lymphoma; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; HLA, human lymphocyte antigen.

Dates of transplantMay 1992–July 2015
Age (years)18 to 77; median, 49
GenderFemale, 341 (40%); male, 516 (60%)
Primary malignancyNHL, 242 (28%); AML, 277 (32%); CML, 48 (5.6%); MDS/MPD, 71 (8.3%); ALL, 74 (8.6%);
CLL, 41 (4.8%); Hodgkin’s disease, 70 (8.2%); multiple myeloma, 24 (2.8%); other hematological
malignancies, 16 (1.9%); other malignancies, 8 (0.9%); nonmalignant hematological disorders,
22 (2.6%)
Graft sourcePeripheral blood, 497 (58%); cord blood, 197 (23%); bone marrow, 163 (19%)
Conditioning intensityStandard intensity myeloablative, 305 (36%); reduced intensity myeloablative, 283 (33%);
nonmyeloablative, 268 (31%)
HLA matchingHLA identical, 604 (70%); HLA mismatch, 253 (30%)
Antibiotics for neutropenic feverNo antibiotics for neutropenic fever, 474 (55%)
Imipenem-cilastatin or piperacillin-tazobactam first-line, 306 (36%)
  Received imipenem-cilastatin only, 6 (0.7%)
  Received piperacillin-tazobactam only, 183 (21%)
  Received both, 117 (14%)
  Also received aztreonam or cefepime, 106 (12%)
  Aztreonam or cefepime first-line, 77 (9%)
  Received aztreonam only, 18 (2.1%)
  Received cefepime only, 40 (4.7%)
  Received both, 19 (2.2%)
  Also received imipenem-cilastatin, 23 (2.7%)